Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

INBX.US - Current Price

$75.94

Company Information

▼
Company Name
Inhibrx Biosciences, Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US45720N1037
Currency: USD
Full Time Employees: 156
Phone: 858 795 4220
Website: https://inhibrx.com
Fiscal Year End: December
IPO Date: May 29, 2024
Description:

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Address:

11025 North Torrey Pines Road, La Jolla, CA, United States, 92037

Directors & Officers

▼
Name Title Year Born
Mr. Mark Paul Lappe Founder, CEO & Chairman 1967
Ms. Kelly Devine Deck B.S., CPA, M.S. Executive VP, CFO & Treasurer 1980
Mr. David J. Matly M.B.A. President 1986
Ms. Bonne Adams M.B.A. Vice President of Operations 1977
Dr. Ashraf Amanullah Ph.D. Executive VP & Chief Technical Operations Officer 1968
Dr. Carlos Bais Ph.D. EVP & Chief Scientific Officer NA
Ms. Leah Pollema J.D. VP, General Counsel & Corporate Secretary NA
Dr. Josep Garcia Ph.D. Executive VP & Chief Clinical Development Officer NA

Shares Statistics

▼
Shares Outstanding: 14.49M
Shares Float: 7.81M
% Insiders: 2,717.40%
% Institutions: 6,551.10%
Short % Float: 6.87%

Valuation Metrics

▼
Enterprise Value: $428.15M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $486.86M
EBITDA: $-96.17M
Book Value: $4.74
Earnings/Share: $-16.57
Profit Margin: 0.00%
Operating Margin: -2,106.85%
ROA (TTM): -26.29%
ROE (TTM): -113.71%
Revenue (TTM): $1.40M
Revenue/Share (TTM): $0.09
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 1,200.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 -1.63 N/A 10,000.00%
Sep 30, 2025 -2.28 -1.57 N/A -4,522.29%
Jun 30, 2025 -1.85 -1.55 N/A -1,935.48%
Mar 31, 2025 -2.80 -1.41 N/A -9,858.16%
Dec 31, 2024 -3.09 -1.44 N/A -11,458.33%
Sep 30, 2024 -2.84 -1.48 N/A -9,189.19%
Jun 30, 2024 125.48 -1.52 N/A 835,526.32%
Mar 31, 2024 -1.44 -1.04 N/A -3,846.15%

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $152.60M $N/A $180.77M $47.18M $133.58M
2023-12-31 $277.92M $N/A $307.89M $264.39M $43.50M
2022-12-31 $273.87M $N/A $290.88M $232.82M $58.06M
2021-12-31 $131.30M $N/A $150.45M $98.07M $52.38M
2020-12-31 $128.66M $N/A $143.74M $68.27M $75.47M
2019-12-31 $11.54M $N/A $26.49M $120.06M $-93.57M
2018-12-31 $2.10M $N/A $9.98M $67.63M $-57.64M
2017-12-31 $13.47M $N/A $17.25M $39.67M $-28.77M
2016-12-31 $20.03M $N/A $21.27M $20.03M $-9.25M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Oct 07, 2025 N/A N/A N/A N/A N/A N/A
Nov 19, 2024 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist